![Katarina Luptakova](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Katarina Luptakova
Keine laufenden Positionen mehr
Vermögen: 22 753 $ am 30.06.2026
Profil
Katarina Luptakova worked at Tesaro, Inc. from 2017 to 2020, serving as Senior Medical Director from 2018 to 2020.
From 2020 to 2021, worked at Constellation Pharmaceuticals, Inc. as Vice President-Clinical Development.
From 2022 to 2023, worked at Xilio Therapeutics, Inc. as Senior Vice President-Medical.
Education includes a doctorate from the University of Commenius.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
XILIO THERAPEUTICS INC 0,04 % | 02.01.2026 | 2.375 ( 0,04 % ) | 22 753 $ | 30.06.2026 |
Ehemalige bekannte Positionen von Katarina Luptakova
| Unternehmen | Position | Ende |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.10.2021 |
| TESARO INC | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2020 |
| XILIO THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Katarina Luptakova
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
15
Beziehungen ersten Grades
4
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for cancer patients | Health Technology |
University of Commenius
 University of Commenius Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Xilio Therapeutics, Inc.
 Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies | Health Technology |
Wählen Sie MarketScreener 
